VIM (Vimentin)

News alerts, weekly reports and conference planners

Entrez ID:

VIM expression	Non Small Cell Lung Cancer	VIM expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
AFP elevation + VIM positive	Sarcoma	AFP elevation + VIM positive	Sarcoma	doxorubicin hydrochloride + ifosfamide Sensitive: C4 – Case Studies doxorubicin hydrochloride + ifosfamide Sensitive : C4	doxorubicin hydrochloride + ifosfamide Sensitive: C4 – Case Studies doxorubicin hydrochloride + ifosfamide Sensitive : C4
CD99 positive + VIM positive	Ewing Sarcoma	CD99 positive + VIM positive	Ewing Sarcoma	OPEC Sensitive: C4 – Case Studies OPEC Sensitive : C4	OPEC Sensitive: C4 – Case Studies OPEC Sensitive : C4
VIM expression	Small Cell Lung Cancer	VIM expression	Small Cell Lung Cancer	AZD2811 Sensitive: D – Preclinical AZD2811 Sensitive : D	AZD2811 Sensitive: D – Preclinical AZD2811 Sensitive : D

Associations(4)